Evidence Explorer / MS-N210 / Unsupported cure claims and safety / Appraised November 2, 2026
The Gonzalez regimen combined large numbers of supplements and porcine pancreatic enzymes with individualized diets and coffee enemas. In the best comparative human study, people who chose this regimen had substantially shorter survival and worse quality of life than those who chose gemcitabine-based chemotherapy.
Evidence at a glance
- Population: 55 people with inoperable pancreatic adenocarcinoma.
- Design: controlled observational comparison after a planned randomized trial could not recruit.
- Groups: 32 chose enzyme therapy and 23 chose gemcitabine-based chemotherapy.
- Results: median survival was 4.3 versus 14.0 months; adjusted mortality hazard ratio 6.96 (P<.001). One-year survival was 16% versus 56%, and quality of life favored chemotherapy (P<.01).
- Evidence label: comparative evidence of worse outcomes with the regimen; not evidence of benefit.
What was studied
The National Cancer Institute originally sponsored a randomized phase III comparison, but most eligible patients refused random assignment. The protocol was changed to a nonrandomized controlled observational study (NCT00003851). Baseline characteristics reported in the paper were not statistically different, but treatment choice can still create residual confounding.
The enzyme regimen included pancreatic enzymes, supplements, detoxification procedures and an organic diet. The primary outcome was overall survival and the secondary outcome was quality of life. A previous 11-person uncontrolled case series reported long survivals in selected patients, but it lacked a comparator and cannot outweigh the later comparative study.
What this evidence cannot establish
Because allocation was by choice, the study cannot prove that the regimen itself caused every difference. Even so, the direction and size of the observed survival and quality-of-life differences provide no support for replacing chemotherapy with the regimen.
Pancreatic enzymes used to treat digestive insufficiency are a different clinical question. Evidence for prescription enzyme replacement after pancreatic disease does not validate this anticancer regimen.
Practical safety context
Coffee enemas can cause rectal injury, infection, fluid or electrolyte disturbances and, rarely, death. Very high pill burdens can impair adherence, worsen nausea and create interactions or contamination risk.
People with pancreatic cancer may need evidence-based pancreatic enzyme replacement, nutrition support, pain control, biliary management and anticancer therapy. Those needs should be assessed directly rather than through an unproven detoxification program.
Questions for the care team
- Is the goal tumor control, digestive enzyme replacement, weight support or symptom relief?
- What survival and quality-of-life evidence applies to the proposed regimen?
- Could coffee enemas, supplements or a restrictive diet worsen dehydration, electrolytes or treatment adherence?
Sources
- NCI PDQ: Gonzalez Regimen
- Controlled comparative study — PMID 19687327; NCT00003851
Source note: The full comparative article and NCI PDQ were checked. The article reports the study’s NCI sponsorship; detailed conflict disclosures were not verified separately. No correction, retraction or expression of concern was identified on November 2, 2026.
This record is educational. Pancreatic enzymes for digestive insufficiency require individualized prescribing; this evidence does not support the Gonzalez regimen as cancer treatment.
